IBM arrives at its July 22 earnings release down more than 21% over the past month and carrying the most concentrated burst of analyst target cuts seen ahead of any recent print.
The analyst activity is the defining feature of this setup. In the 48 hours before this article, Citigroup cut its price target from $375 to $255 and JP Morgan trimmed from $291 to $250 — both maintaining positive ratings but signalling sharply reduced conviction. Those moves followed HSBC's downgrade to Reduce with a $191 target on July 14, and Evercore ISI cutting to $250 from $310. Against that, Oppenheimer raised its target to $350 and Morgan Stanley lifted to $293, keeping the consensus mean at $273 — still roughly 29% above the current price of $212.67. The net message from the Street is not abandonment but recalibration: most analysts still see value from here, yet the magnitude of the target reductions — some slashing by $80 to $120 per share — reflects genuine uncertainty about where IBM's earnings power now sits.
The bull and bear cases heading into Wednesday split on a familiar fault line. Bulls point to IBM's hybrid cloud and AI infrastructure positioning, its quantum computing investments, and a dividend score in the 99th percentile — income support that provides a floor even in a down tape. Bears argue the consulting business is a cyclical liability, that mainframe revenue is structurally pressured, and that growth has relied more on cost discipline than genuine new business wins. With EPS momentum ranking in only the 13th percentile over 30 days and the 28th over 90 days, the bears have had the better of the recent data.
Short interest has risen roughly 16% over the past month to 3.9% of the free float — meaningful movement, though still not an extreme level. What is notable is the contrast with the borrow market: availability remains exceptionally loose at nearly 1,400%, meaning roughly fourteen shares remain available to lend for every one currently borrowed. Short sellers are building positions, but in an environment where doing so is frictionless — cost to borrow is just 0.44%, down about 9% on the week. That looseness removes any squeeze dynamic from the equation. Options positioning, meanwhile, has turned more bullish than usual: the put/call ratio of 0.68 is below its 20-day average of 0.72 and near the 52-week low of 0.62, suggesting the options market is not positioned for a sharp further decline despite the stock's recent severity. Peers including CTSH, ACN, and OKTA all gained 5–8% on the week while IBM fell 26%, underscoring how much of the pressure has been idiosyncratic rather than sector-wide.
The April 22 print produced a 9.6% single-day drop and an 11.2% five-day decline — the sharpest reaction in recent quarters. Wednesday's release will test whether the stock has already discounted a similarly disappointing outcome, or whether the earnings numbers reveal something about IBM's AI and consulting trajectory that resolves the wide gap between current price and a Street consensus that, for all its recent cuts, still sits well above where the stock is trading.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
